![]() | |
Clinical data | |
---|---|
Trade names | Originally Parlodel, subsequently many[1] |
Other names | 2-Bromoergocriptine; CB-154 |
AHFS/Drugs.com | Monograph, International Drug Names |
MedlinePlus | a682079 |
Pregnancy category |
|
Routes of administration | By mouth, vaginal, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 28% of oral dose absorbed |
Metabolism | Extensively liver-mediated |
Elimination half-life | 12–14 hours |
Excretion | 85% bile (feces), 2.5–5.5% urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.042.829 |
Chemical and physical data | |
Formula | C32H40BrN5O5 |
Molar mass | 654.606 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Bromocriptine, originally marketed as Parlodel and subsequently under many brand names,[1] is an ergoline derivative and dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease, hyperprolactinaemia, neuroleptic malignant syndrome, and, as an adjunct, type 2 diabetes.
It was patented in 1968 and approved for medical use in 1975.[2]
brands
was invoked but never defined (see the help page).